abstract |
The invention relates to the use of soluble CTLA4 mutant molecules that block endogenous B7 molecules from binding to their ligands, together with immunosuppressive agents, for the manufacture of pharmaceutical compositions for the treatment of rheumatoid diseases, and in particular rheumatic disease. |